▲ 0.45%
prev close
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Congressional Trades
21
All tracked trades
Members Trading
18
Unique members
Net Activity
+3
12 buys · 9 sells
Members Who Traded This Stock
21 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-01-16 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 59d ago | — | |
| 2025-12-03 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 118d ago | — | |
| 2025-10-24 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 156d ago | — | |
| 2025-09-25 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 162d ago | — | |
| 2025-09-04 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 181d ago | — | |
| 2025-04-15 | AMGNAmgen Inc | Sell | $15,001 - $50,000 | 322d ago | — | |
| 2025-04-08 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 329d ago | — | |
| 2025-02-24 | AMGNAmgen Inc | Buy | $15,001 - $50,000 | 389d ago | — | |
| 2025-02-11 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 225d ago | — | |
| 2024-12-06 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 451d ago | — | |
| 2024-10-23 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 79d ago | — | |
| 2024-08-07 | AMGNAmgen Inc | Buy | $50,001 - $100,000 | 590d ago | — | |
| 2024-08-07 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 273d ago | — | |
| 2024-01-02 | AMGNAmgen Inc | Sell | $15,001 - $50,000 | 801d ago | — | |
| 2023-10-24 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 875d ago | — | |
| 2023-03-06 | AMGNAmgen Inc | Sell | $1,001 - $15,000 | 1078d ago | — | |
| 2022-10-19 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 1239d ago | — | |
| 2022-09-26 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 1275d ago | — | |
| 2022-05-11 | AMGNAmgen Inc | Buy | $1,001 - $15,000 | 1386d ago | — | |
| 2021-03-04 | AMGNAmgen Inc | Buy | $15,001 - $50,000 | 1308d ago | — | |
| 2019-09-27 | AMGNAmgen Inc | Buy | $15,001 - $50,000 | 966d ago | — |
2026-01-16
David J. Taylor
AMGN
Amount
$1,001 - $15,000
Filed
59d ago
2025-12-03
David J. Taylor
AMGN
Amount
$1,001 - $15,000
Filed
118d ago
2025-10-24
Marjorie Taylor Greene
AMGN
Amount
$1,001 - $15,000
Filed
156d ago
2025-09-25
Lisa McClain
AMGN
Amount
$1,001 - $15,000
Filed
162d ago
2025-09-04
Sheldon Whitehouse
AMGN
Amount
$1,001 - $15,000
Filed
181d ago
2025-04-15
Tommy Tuberville
AMGN
Amount
$15,001 - $50,000
Filed
322d ago
2025-04-08
Rob Bresnahan
AMGN
Amount
$1,001 - $15,000
Filed
329d ago
2025-02-24
Jefferson Shreve
AMGN
Amount
$15,001 - $50,000
Filed
389d ago
2025-02-11
Daniel Meuser
AMGN
Amount
$1,001 - $15,000
Filed
225d ago
2024-12-06
Virginia Foxx
AMGN
Amount
$1,001 - $15,000
Filed
451d ago
2024-10-23
Julia Letlow
AMGN
Amount
$1,001 - $15,000
Filed
79d ago
2024-08-07
C. Scott Franklin
AMGN
Amount
$50,001 - $100,000
Filed
590d ago
2024-08-07
Scott Scott Franklin
AMGN
Amount
$1,001 - $15,000
Filed
273d ago
2024-01-02
Michael C. Burgess
AMGN
Amount
$15,001 - $50,000
Filed
801d ago
2023-10-24
Greg Stanton
AMGN
Amount
$1,001 - $15,000
Filed
875d ago
2023-03-06
Josh Gottheimer
AMGN
Amount
$1,001 - $15,000
Filed
1078d ago
2022-10-19
Josh Gottheimer
AMGN
Amount
$1,001 - $15,000
Filed
1239d ago
2022-09-26
Earl Blumenauer
AMGN
Amount
$1,001 - $15,000
Filed
1275d ago
2022-05-11
Josh Gottheimer
AMGN
Amount
$1,001 - $15,000
Filed
1386d ago
2021-03-04
Carol Devine Miller
AMGN
Amount
$15,001 - $50,000
Filed
1308d ago
2019-09-27
Richard W. Allen
AMGN
Amount
$15,001 - $50,000
Filed
966d ago
Recent News
Powered by Polygon.io
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
Teva gewinnt an Dynamik im Biosimilar-Geschäft mit der FDA-Zulassung für PONLIMSI™ (Denosumab-adet) und der Annahme von parallelen Zulassungsanträgen für einen Biosimilar-Kandidaten zu Xolair® (Omalizumab)
Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab)
Trade Timeline
Congressional activity, newest first
David J. Taylor
2026-01-16 · Purchase
$1,001 - $15,000
David J. Taylor
2025-12-03 · Sale
$1,001 - $15,000
Marjorie Taylor Greene
2025-10-24 · Purchase
$1,001 - $15,000
Lisa McClain
2025-09-25 · Sale
$1,001 - $15,000
Sheldon Whitehouse
2025-09-04 · Sale
$1,001 - $15,000
Tommy Tuberville
2025-04-15 · Sale
$15,001 - $50,000
Rob Bresnahan
2025-04-08 · Sale
$1,001 - $15,000
Jefferson Shreve
2025-02-24 · Purchase
$15,001 - $50,000
Daniel Meuser
2025-02-11 · Sale
$1,001 - $15,000
Virginia Foxx
2024-12-06 · Purchase
$1,001 - $15,000
Julia Letlow
2024-10-23 · Purchase
$1,001 - $15,000
C. Scott Franklin
2024-08-07 · Purchase
$50,001 - $100,000
Scott Scott Franklin
2024-08-07 · Purchase
$1,001 - $15,000
Michael C. Burgess
2024-01-02 · Sale
$15,001 - $50,000
Greg Stanton
2023-10-24 · Sale
$1,001 - $15,000
Josh Gottheimer
2023-03-06 · Sale
$1,001 - $15,000
Josh Gottheimer
2022-10-19 · Purchase
$1,001 - $15,000
Earl Blumenauer
2022-09-26 · Purchase
$1,001 - $15,000
Josh Gottheimer
2022-05-11 · Purchase
$1,001 - $15,000
Carol Devine Miller
2021-03-04 · Purchase
$15,001 - $50,000
Richard W. Allen
2019-09-27 · Purchase
$15,001 - $50,000